A greater percentage of patients who received semaglutide tablets 14 mg once daily (8%) and semaglutide tablets 7 mg once daily (4%) discontinued treatment due to gastrointestinal adverse reactions than patients who received placebo (1%)
The researchers used electronic health record data from OneFlorida+ a health research network that includes 10 health systems and clinical partners that serve nearly 20 million patients in Florida, Georgia and Alabama to identify adults who were eligible for anti-obesity medications and had no cancer history
Common GLP-1 GIP B12 formulations compared Compounding pharmacies prepare tirzepatide in several distinct formulations
As might be expected, hypoglycaemic episodes were more common in patients receiving background insulin and sulphonylurea
This is a normal physiological response to weight loss regardless of the method used to achieve it, as documented in systematic reviews of energy expenditure during weight reduction
For years, theyve been the standard care for diabetes management, with as many as 96% of employers including them in their benefits plans in 2024